Co-Authors
This is a "connection" page, showing publications co-authored by Diane Descamps and Anne-Geneviève Marcelin.
Connection Strength
1.807
-
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 Jul; 83(1):119-145.
Score: 0.236
-
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis. 2021 Oct; 40(10):2235-2241.
Score: 0.234
-
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375.
Score: 0.205
-
Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. J Clin Microbiol. 2018 06; 56(6).
Score: 0.192
-
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018 04 01; 73(4):1039-1044.
Score: 0.190
-
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. J Clin Virol. 2017 11; 96:49-53.
Score: 0.184
-
The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 10; 83(4):e1-e3.
Score: 0.060
-
Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2. J Clin Virol. 2020 Sep; 130:104573.
Score: 0.056
-
SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department. J Infect. 2020 11; 81(5):816-846.
Score: 0.056
-
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017. Euro Surveill. 2019 Sep; 24(39).
Score: 0.053
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
Score: 0.052
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
Score: 0.052
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.050
-
Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS One. 2018; 13(6):e0198334.
Score: 0.048
-
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594.
Score: 0.048
-
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
Score: 0.047
-
Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. J Antimicrob Chemother. 2017 08 01; 72(8):2351-2354.
Score: 0.045